Scientific Program

Conference Series Ltd invites all the participants across the globe to attend 7th International Conference on Predictive, Preventive and Personalized Medicine & Molecular Diagnostics Chicago, Illinois, USA.

Submit your Abstract
or e-mail to

[email protected]
[email protected]
[email protected]

Day 2 :

  • Paths Of Biomarkers | Clinical Case Reports | Lifestyle Medicine | Preventive Medicines | Personalized oncology | Immunology infectious disease | Cardiology and vascular medicine | Personalized Medicine & its Innovations | Advances In Molecular Diagnostics | Market Strategies & Challenges In Personalised Medicine | Personalized Drug Therapy | Personalised Medicine In 21st Century | Pharmacogenomics: Convergence of Pharmacology & Genomics | Genomics & Personalized Medicine | Genetics of Ebola Outbreak | Approaches to Stem Cells | Nanotechnology: Future of Personalised Medicine
Location: Doubletree by Hilton Chicago North Shore Conference Center 9599 Skokie Blvd. Skokie IL 60077, USA
Speaker
Biography:

Skalny has completed his PhD at the age of 28 and D.Sc at the age of 38. He is the vice-president of Trace Element – Institute for UNESCO, head of medical elementology chair of RUDN  University, president of ANO Centre for Biotic Medicine, vise-president of Federation of European Societies on Trace Elements and Minerals, chairman of Russian Society of Trace Elements in Medicine, editor-in-chief «Trace Elements in Medicine» (Russia), member of editorial boards of "Journal of Trace Elements in Medicine and Biology" (Elsevier), and "Biological Trace Element Research" (Springer). He has published more than 400 papers, h-index 27 (RU). 

Abstract:

Based on the database containing more than 500,000 cases from Russia and more than 40 countries since 2000 we have developed a medical technology for detection and correction of impaired mineral homeostasis. The basis of the technology is personalized diagnosis of trace element profile of the organism with subsequent correction using monoelement supplements and efficiency control. In contrast, it has been demonstrated that the use of vitamin-mineral complex has low efficiency due to: i) simultaneous administration of numerous minerals and trace elements, that may result in competition and ultimately, reduced bioavailability of one of the components (e.g. iron, copper, zinc); ii) the absence of personalized approach, as the patients obtain a standard commercial complexes of minerals and vitamins irrespectively of their real requirements; iii) problems with assessment of the vitamin-mineral complex efficiency. Therefore, the developed technology significantly improved correction of trace element status of the organism using the principles of personalized medicine. The current technology was successfully used in treatment of trace element disturbances in patients with neuropsychiatric (e.g., autism spectrum disorders), metabolic (e.g. diabetes) disorders, etc. The technology was also used in prophylaxis in persons with extreme lifestyle (soldiers, elite sportsmen, liquidators of nuclear explosion consequences in Chernobyl). Finally, personalized assessment of trace element status allows to reveal the targets for population health policies. In particular, it has been demonstrated that disturbances of trace element status are associated with demographic parameters and morbidity at the population-wide level, being indicative of the possible ‘macro’ effects of ‘micro’ elements.

William G Kearns

President and Director of AdvaGenix

Title: Personalized Genomics within Reproductive Medicine
Speaker
Biography:

William G. Kearns earned his doctorate at Eastern Virginia Medical School and completed his advanced training during a three-year fellowship in medical genetics at the McKusick-Nathans Institute of Genetic Medicine of The Johns Hopkins University School of Medicine. Kearns is well known in the field of genetics, particularly preimplantation genetics, and continues to serve on the faculty of Johns Hopkins as a medical geneticist and associate professor. His duties include training fellows and graduate students in genetics and reproductive endocrinology. Widely known nationally and internationally for his expertise in genetics, Dr. Kearns is uniquely qualified in his ability to devise and implement genetic testing strategies in order to offer IVF patients an opportunity to achieve their goal – a healthy baby.  He brings valuable experience to the diagnostic and research laboratory, including 13 years in starting and directing a preimplantation genetic diagnostic laboratory prior to founding AdvaGenix.

Abstract:

With the rapid pace of progress in the fields of biotechnology, genetics, and genomics, molecular genetic profiling may soon become an integral tool for clinicians to guide individualized management of many medical conditions. Personalized medicine (also termed personalized genomics, genomic medicine, or precision medicine) refers to the application of patient-specific profiles, incorporating genetic and genomic data as well as clinical and environmental factors, to assess individual risks and tailor prevention and disease-management strategies. Personalized medicine involves the use of an individual's genetic profile to guide decisions made in regards to the prevention, diagnosis, and treatment of disease. The definition encompasses a broad range of current clinical practices in which genomic results are used to guide patient care. We will discuss the applications of whole exome sequencing and reproductive medicine based upon a family profile for genetic diseases that are lethal or with high morbidity. Trio data will be presented and discussed regarding the use and application of personalized medicine in respect to a family’s desire to have healthy children.

Speaker
Biography:

Feyrer-Melk has developed a unique and practical background in Lifestyle Medicine, allowing him to effectively leverage technology and behavioral science to enhance personalized care. His extensive work with healthcare professionals and patients is grounded in proven health and lifestyle medicine principles, making him a thought-leader in the field. Dr. Feyrer-Melk serves as the  Director of Lifestyle Medicine at the Optimal Heart Attack & Stroke Prevention Center, the Chief Science Officer for a Med-Tech company (Nudge, LLC)  and is a valued consultant and speaker.  He received his Ph.D. in Exercise Science & Wellness at Arizona State University under the direct guidance of Dr. Charles Corbin, and his M.Ed. in Human Performance at Bowling Green State University under Dr. Richard Bowers. 

Abstract:

Modifiable personal lifestyle factors play significant and interconnected roles in predictive, preventive and personalized patient optimal health. Leveraging available cutting-edge Technology and Behavioral science models can maximize outcomes in a A Personalized Care Model.  This session will help medical program developers and practitioners learn how to seamlessly incorporate and effectively use the proper practice-matched technology. The focus will be on understanding behavioral science as a powerful component of personalized care, identifying the best technologies for the practice, wearable technology, wireless health technology, health apps, and practice platform technologies.

Speaker
Biography:

Shanrong is Director, Computational Biology and Bioinformatics at Pfizer Inc. More than 20 years of experience in computer science, statistics, genetics and computational biology. Deep scientific knowledge in immunology, autoimmune disease, antibody design and biomarker discovery. Have a demonstrated track of records in scientific initiative, innovation, and leadership, including 4 patents, over 20 peer-reviewed publications, and 20 invited talks at international meetings. A recognized pioneer in the field of RNA-seq, big data analysis and cloud computing. Enthusiastic about using NGS technology, computational approaches and informatics systems to drive drug discovery and biological research.

Abstract:

Due to alternative splicing, over 90% of human genes have multiple transcript isoforms. Isoforms of the same gene can play distinct or even opposite biological rules. For instance, gene TP53 has an important role in oncology and different cancer types show different expression profiles of its transcript isoforms. Therefore, it is tempting to quantify RNA-Seq experiments at transcript level, rather than at the gene level. However, estimating the expression of individual isoform is intrinsically challenging because different isoforms of a gene usually have a high proportion of genomic overlap.

Recently, a number of tools have been developed for RNA-seq isoform quantification, including RSEM, Cufflinks, eXpress, Tigar2, Kallisto, Salmon and Sailfish. We performed a systematic evaluation on those methods using both simulated dataset and UHRR and HBRR, and furthermore investigated the impact of gene/isoform structures on the accuracy of isoform quantification. Besides, the library size and relative abundance of different isoforms also influence the quantification results. We determined why RNA-seq is unable to detect less abundant TP53 transcripts and discussed its implications for the general interpretation of RNA-seq data.

Speaker
Biography:

Valdes is a tenured Professor of Pathology and Laboratory Medicine at the University of Louisville’s School of Medicine where he has held the appointments of Distinguished University Scholar and Senior Vice-Chairman. Dr. Valdes received his Ph.D. in Molecular Biophysics and completed Postdoctoral Training in Clinical Chemistry and Toxicology at the University of Virginia.  He is nationally and internationally recognized as a leader in advancing the profession of laboratory medicine; has served on Federal regulatory committees; as president of many national professional organizations; and, has received several distinguished scientist and professional recognition awards. Dr. Valdes has authored more than 260 publications, holds several patents and is a pioneer in establishing the application of personalized and precision medicine via laboratory diagnostics.

a

Abstract:

Polypharmacy, the simultaneous consumption of multiple medications, is not presently considered a health condition such as diabetes, high blood pressure or other chronic health syndromes. The use of multiple medications is growing at an alarming rate with reports documenting a range of 12 to 22 prescriptions being used on average by individuals >50 years of age.  The healthcare consequences range from drug-drug interactions, adverse drug events, prescribing cascades, chronic dependence and hospitalizations, all of which have significant health and economic consequences.  Recent attention on precision medicine and personalizing therapeutics, along with advanced health informatics technology, provides the focus needed to manage this condition and avoid its complications.  First, however, it is important to recognize polypharmacy as a healthcare condition or syndrome and how clinical laboratory diagnostics can play a role in addressing this national problem.  Our discussion centers on the use of laboratory medicine diagnostics in preventing and managing pharmacotherapy with the use of combined pharmacogenetic testing and informatics tools designed to guide selection and dosing of medications.  We urge establishing “polypharmacy” as a recognized healthcare syndrome that, if properly managed based on present technologies, can optimize clinical pharmacotherapy, provide a more precise personalized therapeutics and reduce economic burdens.

Vladislav S Baranov

D.O.Ott’s Institute of Obstetrics,Gynecology and Reproductology

Title: Predictive Medicine Evolution
Speaker
Biography:

Vladislav S.BaranovBorn in 1940, graduated from the State Medical Institute in Lvov (Ukraina), took postgraduate courses and   received a PhD degree in Saint-Petersburg  (Russia) in 1976 .  The    Chief of laboratory for prenatal diagnosis of inherited and inborn diseases at the Ott’s Institute of Obstetrics, Gynecology & Reproduction. Interested in genetic  and cytogenetic aspects of early  development, gene testing of inherited predisposition to common disorders , personalized predictive medicine, gene therapy.  Professor, Corresponding Member of  Russian Academy of  Sciences,   Honorary Scientist, Chief City Expert in Medical Genetics, , The author and co-author   of 29 books   and over 400 scientific papers.

Abstract:

Predictive medicine (PM) as a kid from natural marriage of Human Genome and Medicine has now converted into   quickly expanded area of medical genetics. Main goal of PM may be attributed   to early  identification of  persons,  predisposed to sever complex diseases  before their  obvious  clinical manifestation and  thus  to their prediction, prevention, diagnostics and  efficient personalized  treatment. Progress of PM runs in parallel to spectacular achievements of human genome studies, advances of molecular technologies and their implementation. Started in 2000 as  Predictive Preventive  Personalized  Medicine    (3P -medicine)  it soon  acquired  its Participatory  trait    and  is  now  treated as 4P-medicine.  After short period of recession in 2009-2012 provoked by   “missing heritability” dilemma time for the   robust recovery of PM comes. New system genetics approach (SGA) paved the way to translational medicine which obvious benefits stems from     the complex analysis    of    common disorders. Brief review of   European PPPM Association program of 30 years   development and    similar Precision Medicine program    recently launched in the USA are presented.     Thus   for  20 years period the  PM  has  passed a  long way from primitive  genetic testing    to  systemic genetic  analysis,   from    Genetic  Pass  suggested as far as   2000  to Electronic Genetic Chart of  Health predicted   in 2015.

Speaker
Biography:

Maria Voyatzi completed her PhD at the age of 26 years from the Aristotle Uninersity of Thessaloniki, Greece and postdoctoral studies from the Hospital of Dermatological and Venereological Diseases of THESSALONIKI , State Clinic. She has published more than 15 papers in reputed journals and participated in many hellenic, european and world congresses.

Abstract:

Our purpose is to study the efficacy of the Alexandrite laser (755nm) and the fractional laser when treating pigmentary lesions , the efficacy of the NdYAG Laser ( 1064 nm ) when treating telangiectasias and hemangiomas and the efficacy of the NdYAG Laser and fractional laser on rejuvenation.We used the data from our private office from the past five years  (2011-2015). We treated 1000 patients with freckles with Alexandrite laser, 200 patients with melasma with fractional laser, 100 patients with postinflammatory hyperpigmentation with Alexandrite laser and 60 patients  with postinflammatory hyperpigmentation with fractional laser. We also studied the side effects of the therapies. Alexandrite laser had excellent results on freckles, while the combination of chemical peels and fractional laser was satisfactory for the treatment of melasma. Post inflammatory hyperpigmentation had an intermediate response. The recurrence rates were higher in melasma and the side effects were generally minimal. We also treated 500 patients with telengiectasias and 300 patients with hemangiomas with NdYAG Laser. As far as telangiectasias were concerned, the results were much better when  the face was treated . In contrast, the recurrence rates were much higher when the legs were treated. The results were impressive in almost all cases of cherry hemangiomas. The combination of NdYAG Lasers and fractional lasers on a  monthly basis had satisfactory results in rejuvenation.

Speaker
Biography:

Natalia Malara MD PhD, is a medical oncologist with competence of translational medicine, nanotechnology, toxicology in oncologic and cardiovascular field. She conducts clinical and laboratory investigations focusing her attention on circulating tumor and endothelial cells. He acquired a solid experience in nano-biotechnology techniques with translational approach in medicine collaborating with Bionem group guided by Prof Di Fabrizio. He begin her collaboration with Prof Mollace in July 2009, and since then his research activities are also focused on the project of pre-clinical model finalized to improve pharmacological applications in clinical.

Abstract:

The immunotherapy in cancer is based on the ancient concept of activating an effective immune-mediated reaction direct against tumour cells. How to efficiency activate the immune system in this direction is still a challenge. In fact, despite the rapid increase of knowledge in oncology has contributed to improve immunotherapeutic protocols, some issues remain unresolved. Three key points represent the main challenges causing vaccine-resistance: 1. continuous dynamic changing of cancer tissue determines intrinsic tumour cell alterations; 2. adjustments in the tumour microenvironment; 3. low immune recognition against cancer cells. To learn the molecular changes, that take turns insight tumor during its progression depends on the possibility to analyse cancer cells in real time. Often, the clinicians do not have sources of available tumour cells. In fact, the biopsy of the tumour tissue cannot be repeated many times, for systemic and local complications for the patient . On the other hand, the development of vaccine-resistance depends by the heterogeneity of tumor tissue. The cancer heterogeneity represents a limit in the design and application of immunotherapy adopting specific immunogenic protein. The CTCs represent the cancer cell population released in the blood stream and can be considered like a cellular “summary” of the systemic cancer disease. Recent studies report standardized methodology to collect and short-time in vitro expanded CTCs. The protocol, making available cancer cells without modifying their heterogeneity, provides interesting solutions to overcome the degree of immune tolerance and, on the other hand, to reduce the autoimmune spiral triggered by the cryptic epitopes.

Speaker
Biography:

Livija Sušić has completed Faculty of Medicine at the age of 24 years from J. J. Strossmayer University, Osijek, Croatia. She is internist and head of specialist-consultation Department in Health Centre Osijek. She is also a Post – Graduate student on J. J. Strossmayer University, Faculty of Medicine. She is at the beginning of the scientific career, published 4 papers till now.  

 

 

Abstract:

 

Arrhythmogenic right ventricular cardiomyopathy (ARVC) is an inherited cardiomyopathy commonly transmitted as an autosomal dominant trait, characterized by incomplete penetrance and variable expressivity. So far 13 disease genes have been identified, responsible for approximately 60% of all ARVC cases. The pathological consists of  a dystrophy of right ventricle (RV)  myocardium with fibro-fatty replacement which leads to RV aneurysms dilatation, providing a supstrate for life-treatening arrhythmias. The course of the disease is divided into four main stages: subclinical, overt electrical, RV dysfunctional and  biventricular late stage. Dilatation of the RV and global or focal wall motion abnormalities are supposed to increase the risk of thrombus formation.  It is estimated that annual thromboembolic incidence is 0,5/100 patients, which is extremely rare considering the prevalence of disease being between 1 per 2000 and 1 per 5000 inhabitants. We present the case of 61-year-old female patient with multiple thrombi  in a cavity of RV who had a combination of ARVC and hereditary trombophilia (homozygous mutation on 5G PAI- 1 allele). It is very rare combination and diagnostic challenge for us. Considering that diagnostic protocol went retrograde from rare complication according to cause and that it included anamnesis, laboratory tests, interpretation of ECG and holter ECG monitoring, multimodal  imaging methods ( TTE, TEE, MRI, multislice CT, PET CT, coronarography), surgical procedure with extirpation of multiple RV masses and pathohistological analysis, and molecular markers of inherited thrombophilia, we believe that this is phenomenal example of the application of personalized medicine into practice.